Carmen M. Warren
Research Subjects
Carmen M. Warren has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Bot
Capstan Therapeutics, San Diego, California
7 shared publications - Christina To
Kite, a Gilead Company, Santa Monica, California
7 shared publications - Craig A. Portell
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Department of Medicine, Charlottesville, USA
7 shared publications - Ethan G. Aguilar
Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA
7 shared publications - Jason R. Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
7 shared publications - Justin Budka
Kite, a Gilead Company, Santa Monica, CA
7 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 17 November 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (1) , 21-33
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products. Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed. This article is featured in Selected Articles from This Issue, p. 4
- 17 November 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (1) , 21-33
Open AccessProduct Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products. Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed. This article is featured in Selected Articles from This Issue, p. 4